

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L4: Entry 1 of 6

File: PGPB

Apr 26, 2007

DOCUMENT-IDENTIFIER: US 20070092532 A1

TITLE: Arthritis vaccines and methods

Brief Summary Text:

[0005] Anti-inflammatory agents used to treat RA traditionally include aspirin and non-steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen (Motrin.TM., Advil.TM.), fenoprofen, indomethacin, naproxen (Naprosyn.TM., Alleve.TM.), and others. These are widely used medications that are effective in relieving pain and inflammation associated with RA. However, the side effects associated with frequent use of many of these medications include life-threatening gastrointestinal bleeding and kidney damage. Similar drugs, called Cox-2 inhibitors, while effective, have recently encountered safety concerns regarding a risk of cardiovascular problems. Currently, there are three available--valdecoxib (Bextra.TM.), rofecoxib (Vioxx.TM.) and celecoxib (Celebrex.TM.). The benefits from these medications may take weeks or months to be apparent. Because they are associated with possible adverse side effects, monitoring of patients, including blood tests, while on these medications is advised.

Description of Disclosure:

[0061] For example, it is known that dogs, especially several larger breeds are most prone to arthritis: Golden Retrievers, Labrador Retrievers, German Shepherds, Newfoundlands and St. Bernards. These breeds of dogs are also known for developing a higher incidence of hip dysplasia as compared to other breeds, which are not prone to arthritis. Cats also experience severe and debilitating arthritis disease. For example, erosive polyarthritis in cats has been described as resembling RA in man. (See Pedersen, NC et al., Am. J. Vet. Res. (1980) 41(4): 522-535.) Equine arthritis is as complex and diverse as arthritis in humans. Horses (Equus caballus) are naturally prone to suffer osteoarthritis later in life. In some veterinary circles, arthritis in the horse is commonly associated with lameness and often reduces the horse's productive work years. One documented etiology of lameness occurs when an afflicted horse experiences "navicular disease." Chronic navicular disease can be caused by arthritis of the navicular bone and associated structures. (March, L., "Navicular disease is a common lameness problem in horses." University of Illinois, College of Veterinary Medicine (Feb. 06, 1995)). The present invention extends to vaccination compositions and methods of preventing the onset of arthritis in companion animals and other work animals for example without limitation, horses.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L4: Entry 4 of 6

File: USPT

Nov 9, 1999

DOCUMENT-IDENTIFIER: US 5981579 A

TITLE: Use of nitrovasodilators for treatment of disease or stress conditions in a non-human mammal

Brief Summary Text (46):

In a review of the concepts and current therapy of the condition, Yelle in Equine Veterinary Journal (1986) 18, 156-158 concluded that laminitis should be considered as an emergency condition requiring immediate therapy. The acute phase of the disease may be protracted and incur large expenses usually with a poor prognosis. Many laminitic horses require life long attention. A variety of treatments are proposed, including local nerve blocks and systemic analgesics to control pain, antibiotics to control infection, non-steroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and padding to maintain local hoof integrity.

Detailed Description Text (43):

Transdermal GTN "patches" at the doses shown in table 2 are applied to horses and ponies to treat navicular disease, a vasospastic/vasoconstrictive condition of distal sesamoids.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

# Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20030163086 A1

L2: Entry 1 of 3

File: PGPB

Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030163086

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030163086 A1

TITLE: Fluid delivery device

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Denyer, Stephen	Lewes		GB
Hillery, Anya	Madrid		ES
Whitfield, Hugh	Chalfont St Giles		GB
Choong, Simon	London		GB
El-Madani, Abdulla	Brighton		GB

US-CL-CURRENT: 604/102.01; 606/192

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 2. Document ID: EP 702943 A1

L2: Entry 2 of 3

File: EPAB

Mar 27, 1996

PUB-NO: EP000702943A1

DOCUMENT-IDENTIFIER: EP 702943 A1

TITLE: Leg orthosis

PUBN-DATE: March 27, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
BAISE, MONIQUE DR	DE

INT-CL (IPC): A61F 5/01; A61F 5/14

EUR-CL (EPC): A61F005/01

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

3. Document ID: DE 4430493 A1, RU 2142759 C1, EP 702943 A1, EP 702943 B1, DE 59506149 G, ES 2134979 T3

L2: Entry 3 of 3

File: DWPI

Feb 29, 1996

DERWENT-ACC-NO: 1996-130213

DERWENT-WEEK: 200043

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Foot support device for a flat pes valgus - has a closed plastic section with a side opening in the heel area and a closure mechanism

INVENTOR: BAISE, M

PRIORITY-DATA: 1994DE-4430493 (August 27, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 4430493 A1</u>	February 29, 1996		008	A61F005/01
<u>RU 2142759 C1</u>	December 20, 1999		000	A61F005/01
<u>EP 702943 A1</u>	March 27, 1996	G	008	A61F005/01
<u>EP 702943 B1</u>	June 9, 1999	G	000	A61F005/01
<u>DE 59506149 G</u>	July 15, 1999		000	A61F005/01
<u>ES 2134979 T3</u>	October 16, 1999		000	A61F005/01

INT-CL (IPC): A61F 5/01; A61F 5/04; A61F 5/14

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	IPC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

novicular

3

Display Format:  Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)[Generate Collection](#)[Print](#)

L4: Entry 1 of 6

File: PGPB

Apr 26, 2007

DOCUMENT-IDENTIFIER: US 20070092532 A1

TITLE: Arthritis vaccines and methods

Brief Summary Text:

[0005] Anti-inflammatory agents used to treat RA traditionally include aspirin and non-steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen (Motrin.TM., Advil.TM.), fenoprofen, indomethacin, naproxen (Naprosyn.TM., Alleve.TM.), and others. These are widely used medications that are effective in relieving pain and inflammation associated with RA. However, the side effects associated with frequent use of many of these medications include life-threatening gastrointestinal bleeding and kidney damage. Similar drugs, called Cox-2 inhibitors, while effective, have recently encountered safety concerns regarding a risk of cardiovascular problems. Currently, there are three available--valdecoxib (Bextra.TM.), rofecoxib (Vioxx.TM.) and celecoxib (Celebrex.TM.). The benefits from these medications may take weeks or months to be apparent. Because they are associated with possible adverse side effects, monitoring of patients, including blood tests, while on these medications is advised.

Description of Disclosure:

[0061] For example, it is known that dogs, especially several larger breeds are most prone to arthritis: Golden Retrievers, Labrador Retrievers, German Shepherds, Newfoundlands and St. Bernards. These breeds of dogs are also known for developing a higher incidence of hip dysplasia as compared to other breeds, which are not prone to arthritis. Cats also experience severe and debilitating arthritis disease. For example, erosive polyarthritis in cats has been described as resembling RA in man. (See Pedersen, NC et al., Am. J. Vet. Res. (1980) 41(4): 522-535.) Equine arthritis is as complex and diverse as arthritis in humans. Horses (Equus caballus) are naturally prone to suffer osteoarthritis later in life. In some veterinary circles, arthritis in the horse is commonly associated with lameness and often reduces the horse's productive work years. One documented etiology of lameness occurs when an afflicted horse experiences "navicular disease." Chronic navicular disease can be caused by arthritis of the navicular bone and associated structures. (March, L., "Navicular disease is a common lameness problem in horses." University of Illinois, College of Veterinary Medicine (Feb. 06, 1995)). The present invention extends to vaccination compositions and methods of preventing the onset of arthritis in companion animals and other work animals for example without limitation, horses.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

## Refine Search

### Search Results -

Terms	Documents
L2 and nsaid	6

**Database:**

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

**Search:**






### Search History

**DATE:** Wednesday, August 15, 2007   
 [Purge Queries](#)   
 [Printable Copy](#)   
 [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L4</u>	L2 and nsaid	6	<u>L4</u>
<u>L3</u>	L2 and diclofenac	2	<u>L3</u>
<u>L2</u>	navicul\$ same horse	71	<u>L2</u>
<u>L1</u>	navicul\$	850	<u>L1</u>

END OF SEARCH HISTORY

## Refine Search

### Search Results -

Terms	Documents
lameness same diclofenac	16

**Database:**

US Pre-Grant Publication Full-Text Database  
US Patents Full-Text Database  
US OCR Full-Text Database  
EPO Abstracts Database  
JPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L3

[Refine Search](#)[Recall Text](#)[Clear](#)[Interrupt](#)

### Search History

**DATE:** Wednesday, August 15, 2007    [Purge Queries](#)    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L3</u>	lameness same diclofenac	16	<u>L3</u>
<u>L2</u>	novicular	3	<u>L2</u>
<u>L1</u>	novicular same diclofenac	0	<u>L1</u>

END OF SEARCH HISTORY

## Refine Search

### Search Results -

Terms	Documents
novicular	3

**Database:**

US Pre-Grant Publication Full-Text Database  
US Patents Full-Text Database  
US OCR Full-Text Database  
EPO Abstracts Database  
JPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L2

**Refine Search****Recall Text** **Clear****Interrupt**

### Search History

**DATE:** Wednesday, August 15, 2007    [Purge Queries](#)    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L2</u>	novicular	3	<u>L2</u>
<u>L1</u>	novicular same diclofenac	0	<u>L1</u>

END OF SEARCH HISTORY